Clearance of Lormetazepam, Midazolam, and Their Conjugated Metabolites by Continuous Venovenous Hemofiltration During Prolonged Sedation in Critically Ill Patients With COVID-19-Associated Acute Respiratory Distress Syndrome

J Clin Pharmacol. 2022 Apr;62(4):568-570. doi: 10.1002/jcph.2005. Epub 2022 Jan 3.
No abstract available

Keywords: COVID-19; Conjugated metabolites; Continuous venovenous hemofiltration; Lormetazepam; Midazolam; Prolonged sedation.

Publication types

  • Letter

MeSH terms

  • Aged
  • COVID-19 / complications
  • COVID-19 Drug Treatment*
  • Continuous Renal Replacement Therapy
  • Critical Illness / therapy
  • Deep Sedation*
  • Humans
  • Hypnotics and Sedatives / metabolism*
  • Hypnotics and Sedatives / pharmacokinetics*
  • Hypnotics and Sedatives / therapeutic use
  • Lorazepam / analogs & derivatives*
  • Lorazepam / metabolism
  • Lorazepam / pharmacokinetics
  • Lorazepam / therapeutic use
  • Male
  • Midazolam / metabolism*
  • Midazolam / pharmacokinetics*
  • Midazolam / therapeutic use
  • Middle Aged
  • Respiratory Distress Syndrome / complications
  • Respiratory Distress Syndrome / drug therapy*

Substances

  • Hypnotics and Sedatives
  • lormetazepam
  • Lorazepam
  • Midazolam